New Delhi: Days after the Centre highlighted India’s progress in reducing TB mortality, following the release of the WHO Global Tuberculosis Report 2026, public health network Jan Swasthya Abhiyan India (JSAI) has flagged the country’s continuing high disease burden, calling for greater transparency in TB incidence estimates and programme reporting.
Citing the WHO report, the network pointed out that 10.6 million people developed TB and 1.13 million died globally in 2025. India continues to account for approximately one-fourth of global TB cases and 23% of global TB deaths, despite a 38% decline in TB mortality since 2015.
JSAI raised the issue along with several other critical concerns regarding the implementation and performance of the National Tuberculosis Elimination Programme (NTEP) in a letter to the Centre, seeking urgent corrective measures and greater public accountability.
It highlighted that WHO has kept India’s latest TB incidence estimates under review pending analysis of district-level sentinel surveillance data as it called for transparent and scientifically robust disease-burden estimation.
“We are particularly concerned that India’s annual India TB Report has not been updated on the Central TB Division’s public annual-report portal beyond the 2024 edition. The absence of a current, comprehensive annual report with state-wise and district-wise programme performance data limits independent assessment and public accountability,” it added.
JSAI flagged critical gaps in the procurement and distribution of anti-TB medicines as one of its key concerns.
Citing an investigation published by The Indian Express in December 2024, the organisation said the central supply of essential fixed-dose combination anti-TB medicines had witnessed significant disruptions, with supplies of intensive-phase medicines declining 56.5 per cent in 2023 compared with 2022, while continuation-phase supplies fell 23 per cent.
It also referred to the Comptroller and Auditor General’s Report No. 8 of 2024, which identified the expiry of anti-TB medicines worth ₹40.75 crore across five Government Medical Store Depots between July 2017 and February 2023.
The organisation has sought an independent nationwide assessment of medicine availability, alongside monthly state-wise and district-wise disclosure of stock levels, stock-out days and emergency procurement. It has also called for real-time monitoring of medicine availability at individual TB treatment facilities, adequate buffer stocks and accountability for procurement delays and expired medicines.
